BACKGROUND: The purpose of this study was: (1) to document the critical requirement of cystine for growth of human tumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter x(c)(-) in head and neck FaDu xenografts. METHODS: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using Western blot, spectrophotometry, and immunohistochemistry, respectively. RESULTS: Depletion of cystine from the medium inhibited tumor cell growth. Treatment of FaDu tumor with a therapeutic dose of irinotecan resulted in depression of xCT protein levels, leading to tumor growth retardation and downregulation of GSH with increased reactive oxygen species (ROS). The accumulation of ROS correlated with increased DNA damage as evidenced by increased H2AX. CONCLUSION: Depression of xCT protein by irinotecan resulted in downregulation of GSH and increase in ROS, which could be the other possible mechanisms of DNA damage by irinotecan. Copyright 2010 S. Karger AG, Basel.
BACKGROUND: The purpose of this study was: (1) to document the critical requirement of cystine for growth of humantumor cells in vitro, and (2) to determine the effect of the anticancer agent irinotecan on the cystine transporter x(c)(-) in head and neck FaDu xenografts. METHODS: Cell growth was measured by sulforhodamine B assay. xCT protein, glutathione (GSH) and DNA damage were determined using Western blot, spectrophotometry, and immunohistochemistry, respectively. RESULTS: Depletion of cystine from the medium inhibited tumor cell growth. Treatment of FaDu tumor with a therapeutic dose of irinotecan resulted in depression of xCT protein levels, leading to tumor growth retardation and downregulation of GSH with increased reactive oxygen species (ROS). The accumulation of ROS correlated with increased DNA damage as evidenced by increased H2AX. CONCLUSION:Depression of xCT protein by irinotecan resulted in downregulation of GSH and increase in ROS, which could be the other possible mechanisms of DNA damage by irinotecan. Copyright 2010 S. Karger AG, Basel.
Authors: Vishal S Narang; Giovanni M Pauletti; Peter W Gout; Donna J Buckley; Arthur R Buckley Journal: Chemotherapy Date: 2007-03-15 Impact factor: 2.544
Authors: A Banjac; T Perisic; H Sato; A Seiler; S Bannai; N Weiss; P Kölle; K Tschoep; R D Issels; P T Daniel; M Conrad; G W Bornkamm Journal: Oncogene Date: 2007-09-10 Impact factor: 9.867
Authors: Milind M Javle; Shousong Cao; Farukh A Durrani; Lakshmi Pendyala; David D Lawrence; Patrick F Smith; Patrick J Creaven; Diane C Noel; Renuka V Iyer; Youcef M Rustum Journal: Clin Cancer Res Date: 2007-02-01 Impact factor: 12.531
Authors: Philip M Tedeschi; HongXia Lin; Murugesan Gounder; John E Kerrigan; Emine Ercikan Abali; Kathleen Scotto; Joseph R Bertino Journal: Mol Pharmacol Date: 2015-07-28 Impact factor: 4.436
Authors: Jianmin Wang; Antonios Papanicolau-Sengos; Sreenivasulu Chintala; Lei Wei; Biao Liu; Qiang Hu; Kiersten Marie Miles; Jeffrey M Conroy; Sean T Glenn; Manuela Costantini; Cristina Magi-Galluzzi; Sabina Signoretti; Toni Choueiri; Michele Gallucci; Steno Sentinelli; Vito M Fazio; Maria Luana Poeta; Song Liu; Carl Morrison; Roberto Pili Journal: Oncotarget Date: 2016-05-24